NCT00995488View on ClinicalTrials.gov

Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Urothelial CancerBladder Cancer
Interventions
DRUG

ABI-007 (Abraxane®)

ABI-007 is a novel albumin-bound paclitaxel combining a protein with a chemotherapeutic agent in the particle form.

Trial Locations (1)

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

University of Michigan Rogel Cancer Center

OTHER